(888) 645-1617

News

Sort By

Endo Announces $775 Settlement for Transvaginal Mesh Claims

gavel with a stack of hundred dollar bills over a settlement form

Trying to end its surgical mesh legal woes, Endo International says it has reached agreements and will pay out $775 million to settle the approximately 22,000 remaining, known claims filed by women in the U.S. who say they were injured from procedures that used the Irish company’s transvaginal mesh.

Under agreements Endo has reached with plaintiffs, the company will start making installment payments in the fourth quarter of this year, continuing until the end of 2019. The $775 million is expected to cover all known international mesh product liability claims as well.

That amount is on top of the $2.8 billion Endo has previously agreed to pay in 48,0000 cases filed since 2013, according to Endo’s December 31, 2016 filing with the U.S. Securities and Exchange Commission. In 2016 alone, the company paid out more than $1.1 billion in mesh legal settlements.

“Beginning in the second quarter of 2017, we aggressively executed a settlement strategy in connection with Endo’s mesh litigation. We believe it is a very important milestone for Endo to have reached agreements to resolve virtually all known U.S. mesh product liability claims,” Paul Campanelli, Endo’s president and chief executive officer, said Aug. 7, 2017. “While it remains possible that additional claims will be filed, we believe today’s announcement will assist most mesh claimants to move forward with their lives and will permit Endo to move forward with an even greater focus on executing against our core strategic priorities.”

The $775 million settlement contributed to the company’s consolidated net loss of nearly $1.4 million for the second quarter of 2017.

State Attorneys General Investigate Mesh

But Endo may also be facing legal action from various states’ attorneys general in connection with transvaginal surgical mesh products.

According to the December SEC filing, Endo has continued to cooperate with investigations by California and other states, dating back to at least October 2012 when the company was contacted regarding “a civil investigation initiated by a number of state attorneys general into mesh products.”

In May 2016, Kamala D. Harris, who was then the attorney general of California, filed a lawsuit against Johnson & Johnson, accusing it of false advertising and deceptive marketing of its surgical mesh products for women. The lawsuit said that J&J failed to warn patients and doctors of possible, severe complications, and misrepresented the frequency and severity of the risk.

Transvaginal mesh is a product made of plastic or animal tissue that is implanted vaginally to repair pelvic organ prolapse or stress urinary incontinence, conditions which can occur in women following menopause, childbirth, or a hysterectomy.

FDA Calls Mesh ‘High Risk’ Medical Device

The U.S. Food and Drug Administration has classified the mesh as a “high risk” medical device, and some surgeons have stopped using it. In July 2011, the FDA issued a notification stating that adverse events associated with transvaginal mesh are not rare, and it questioned its effectiveness for treatment of pelvic organ prolapse compared to other available treatments.

In March 2016, Endo closed Astora Women’s Health division subsidiary, which manufactured the mesh, in an attempt to stem the costs of the continuing litigation. Other companies, such as J&J, have stopped selling some product lines.

On another front, Endo bowed to a request from the FDA on July 6 when it acceded to the agency’s unprecedented request that it remove the opioid drug Opana ER from the U.S. market because of concerns about addiction. The drug is twice as powerful as Oxycontin and three times as powerful as morphine.

Opana ER was the company’s highest revenue generator last year, bringing in nearly $159 million in revenue. Endo said it will cease shipments by Sept. 1.

In second quarter financial results released Aug. 8, Endo said it experienced a 15 percent decrease of revenues from branded pharmaceuticals, compared to the same quarter in 2016, partly because of generic competition and the withdrawal of Opana ER from the market.

Last modified: August 9, 2017


Elaine Silvestrini is a career journalist with a strong desire to learn, explain, and help people. While working at Drugwatch, Elaine has reported on breaking news involving prescription drugs and medical devices and has written pieces on several large pharmaceutical companies and other topics. She is dedicated to telling people what they need to know about developments in the news, and helping consumers understand what they can do when something goes wrong with their drugs and medical devices.

Hide Sources

  1. Endo. (2017, August 8). Endo Reports Second-Quarter 2017 Financial Results. Retrieved from: http://www.endo.com/news-events/press-releases?c=123046&p=irol-newsArticle&ID=2292448
  2. United States Securities and Exchange Commission. (2016, December 31). Form 10-K. Endo International PLC. Retrieved from: file:///C:/Users/esilvestrini/Downloads/10-K%20Final%20(1).pdf
  3. Endo. (2017, August 7). Endo Announces Agreements to Resolve Virtually All Known U.S. Mesh Product Liability Claims. Retrieved from: http://www.endo.com/news-events/press-releases?c=123046&p=irol-newsArticle&ID=2292342
Free Transvaginal Mesh Case Review

Experiencing complications and side effects from your Transvaginal Mesh?
Get Help Now